Cost-effectiveness of transfusion of platelet components prepared with pathogen inactivation treatment in the United States
نویسندگان
چکیده
منابع مشابه
Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial.
A nucleic acid-targeted photochemical treatment (PCT) using amotosalen HCl (S-59) and ultraviolet A (UVA) light was developed to inactivate viruses, bacteria, protozoa, and leukocytes in platelet components. We conducted a controlled, randomized, double-blinded trial in thrombocytopenic patients requiring repeated platelet transfusions for up to 56 days of support to evaluate the therapeutic ef...
متن کاملCost effectiveness of lenalidomide in the treatment of transfusion-dependent myelodysplastic syndromes in the United States.
Lenalidomide has been approved for the treatment of transfusion-dependent low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a chromosome 5q deletion with or without additional cytogenetic abnormalities. We evaluated the cost effectiveness of lenalidomide versus best supportive care (BSC) in these patients. We developed a decision analytic model to compare costs and out...
متن کاملEFFICACY OF AMOTOSALEN HCL PLATELETS 1 TRANSFUSION OF POOLED BUFFY COAT PLATELET COMPONENTS PREPARED WITH PHOTOCHEMICAL PATHOGEN INACTIVATION TREATMENT: THE euroSPRITE TRIAL
word count = 273 Text word count = 5,570
متن کاملPathogen Inactivation of Platelet and Plasma Blood Components for Transfusion Using the INTERCEPT Blood System™
BACKGROUND: The transmission of pathogens via blood transfusion is still a major threat. Expert conferences established the need for a pro-active approach and concluded that the introduction of a pathogen inactivation/reduction technology requires a thorough safety profile, a comprehensive pre-clinical and clinical development and an ongoing hemovigilance program. MATERIAL AND METHODS: The INTE...
متن کاملPathogen Inactivation of Platelet and Plasma Blood Components for Transfusion Using the INTERCEPT Blood SystemTM
Background: The transmission of pathogens via blood transfusion is still a major threat. Expert conferences established the need for a pro-active approach and concluded that the introduction of a pathogen inactivation/reduction technology requires a thorough safety profile, a comprehensive pre-clinical and clinical development and an ongoing hemovigilance program. Material and Methods: The INTE...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical Therapeutics
سال: 2003
ISSN: 0149-2918
DOI: 10.1016/s0149-2918(03)80288-6